CoSMeD

CoSMeD estimates 5-year survival probability for left-sided and right-sided colorectal cancer patients using molecular data.

Key Features:

• Multi-Omics Data Integration: Integrates gene expression, DNA methylation, and microRNA expression data from The Cancer Genome Atlas (TCGA).
• Prognostic Biomarker Identification: Identifies side-specific prognostic biomarkers (6 for left-sided and 28 for right-sided colorectal cancer) using specificity measures and robust likelihood-based survival analysis to predict 5-year survival.
• External Validation: Validates the prognostic value of identified side-specific genes using additional datasets from the Gene Expression Omnibus (GEO).
• Integration with Clinical Data: Combines molecular biomarkers with clinical data to improve discriminatory ability and calibration of side-specific 5-year survival predictions.

Scientific Applications:

• Survival Prognostication: Provides molecularly informed 5-year survival probability estimates for left- and right-sided colorectal cancer patients.
• Side-Specific Biomarker Research: Enables investigation of molecular differences between left-sided and right-sided colorectal cancer through identified gene sets.
• Personalized Treatment Stratification: Supports development of individualized treatment protocols by integrating side-specific molecular biomarkers with clinical information.

Methodology:

Integrates TCGA gene expression, DNA methylation, and microRNA expression data; applies specificity measures and robust likelihood-based survival analysis to identify prognostic biomarkers; validates prognostic genes using GEO datasets.